By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website –
Check out our openings –

Key Statistics

Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN



Sanofi US 


Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotech 

Company News
Regeneron (REGN) And Teva (TEVA) Provide Update On Fasinumab Clinical Development Programs 10/17/2016 1:35:33 PM
FDA Slaps Hold on Regeneron (REGN), Teva (TEVA)'s Pain Drug Fasinumab 10/17/2016 5:27:35 AM
Regeneron (REGN) Bets $315 Million on Ocular Therapeutix (OCUL) for an Upgraded Form of Eylea 10/13/2016 5:30:27 AM
Regeneron (REGN) Could Have Another Blockbuster in This Drug 10/10/2016 6:47:29 AM
Regeneron (REGN) To Report Third Quarter 2016 Financial And Operating Results And Host Conference Call And Webcast On November 4, 2016 10/7/2016 8:46:03 AM
Why Ophthotech (OPHT) Is Trading Down On Regeneron (REGN)'s News 10/3/2016 7:28:45 AM
Regeneron (REGN), Sanofi (SNY) Tout Phase III Dupixent Data 10/3/2016 6:35:22 AM
Regeneron (REGN) Faces Setback as Eylea Combo Drug Flunks Phase II Test 9/30/2016 7:17:41 AM
Regeneron (REGN) And Sanofi (SNY) Announce Dupilumab Biologics License Application Accepted For Priority Review By U.S. FDA 9/26/2016 7:44:12 AM
Teva (TEVA) Forges $2.6 Billion Deal to Buy Into Regeneron (REGN)'s Pain Drug Fasinumab 9/20/2016 5:47:48 AM